Overview

Phase 1b/2, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

An Open-label Study using ASP-1929 Photoimmunotherapy in Combination with anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors in patients with head and neck and cutaneous squamous cell carcinoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Rakuten Medical, Inc.

Treatments:

Cemiplimab
Pembrolizumab